Danziten, a nilotinib formulation, approved by FDA for chronic myeloid leukemia without mealtime restrictions, enhancing adherence. Danziten offers equivalent efficacy to Tasigna, with improved ...
The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results